{"id":"W4211106526","doi":"10.1158/1078-0432.ccr-21-3045","title":"Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Gilead Sciences; National Cancer Institute; National Institutes of Health; Breast Cancer Alliance; Sierra Oncology; Ipsen; Genentech; Deutsche Krebshilfe; G1 Therapeutics; Stand Up To Cancer; EMD Serono; Mersana Therapeutics; Merck KGaA; Dana-Farber/Harvard Cancer Center; GlaxoSmithKline; Breast Cancer Research Foundation; Pfizer; Symphogen; Carrick Therapeutics; American Association for Cancer Research; AstraZeneca; Eli Lilly and Company; Astex Pharmaceuticals","keywords":"Olaparib; PARP inhibitor; Clinical trial; Breast cancer; Cancer; Phases of clinical research; Poly ADP ribose polymerase","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001270472,0.0009419149,0.001399528,0.0003059781,0.0002470257,0.0007009075,0.0004434071,0.0006379469,0.005506341],"category_scores_gemma":[0.0008830249,0.0002670876,0.0006447727,0.0002774035,0.0003628342,0.0004934634,0.0002808845,0.001985316,0.0008957727],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005542273,"about_ca_system_score_gemma":0.001134696,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002867384,"about_ca_topic_score_gemma":0.001120903,"domain_scores_codex":[0.9996541,0.0001992413,0.00001600476,0.00004852078,0.00003628913,0.00004582164],"domain_scores_gemma":[0.9995705,0.00008137345,0.0001298442,0.00003156779,0.00002744604,0.0001591815],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7363423,0.03344616,0.007865724,0.00134844,0.001290654,0.0003167347,0.0001697499,0.002353537,0.04077463,0.0002835756,0.006354892,0.1694537],"study_design_scores_gemma":[0.6934753,0.2795354,0.01531632,0.00008701836,0.0003324116,0.0006085869,0.0000363902,0.001613503,0.00313976,0.0002925785,0.005537201,0.00002551196],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870378,0.00435582,0.0006282012,0.0009504527,0.0001525721,0.002784444,0.001256179,0.0001339255,0.002700643],"genre_scores_gemma":[0.9863498,0.002057383,0.002152879,0.001266813,0.0002385547,0.002580928,0.002649164,0.00002708814,0.00267735],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005506341,"threshold_uncertainty_score":0.01842052,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2879403571378599,"score_gpt":0.59430337590085,"score_spread":0.3063630187629901,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}